main results and the role of chance: In 21 countries where all clinics reported to the ART register, a total of 399 020 ART cycles were performed in a population of 373.8 million, corresponding to 1067 cycles per million inhabitants. For IVF, the clinical pregnancy rates per aspiration and per transfer were 28.9 and 32.9%, respectively and for ICSI, the corresponding rates were 28.7 and 32.0%. In FER cycles, the pregnancy rate per thawing was 20.9%; in ED cycles, the pregnancy rate per transfer was 42.3%. The delivery rate after IUI-H was 8.3 and 13.4% after IUI-D. In IVF and ICSI cycles, 1, 2, 3 and 4+ embryos were transferred in 24.2, 57.7, 16.9 and 1.2%, respectively. The proportions of singleton, twin and triplet deliveries after IVF and ICSI (combined) were 79.8, 19.4 and 0.8%, respectively, resulting in a total multiple delivery rate of 20.2%, compared with 21.7% in 2008, 22.3% in 2007, 20.8% in 2006 and 21.8% in 2005. In FER cycles, the multiple delivery rate was 13.0% (12.7% twins and 0.3% triplets). Twin and triplet delivery rates associated with IUI cycles were 10.4/0.7% and 10.3/0.5%, following treatment with husband and donor semen, respectively.
Introduction
This report is the 13th annual European Society of Human Reproduction and Embryology (ESHRE) publication on European data on assisted reproductive technology (ART). The 12 previous reports, also published in Human Reproduction (Nygren and Nyboe Andersen, 2001a,b; Nygren and Nyboe Andersen, 2002; Nyboe Andersen et al., 2004 , 2005 , 2006 , 2008a de Mouzon et al., 2010 de Mouzon et al., , 2012 Ferraretti et al., 2012) , covered treatment cycles from 1997 to 2008. As in the last report, the printed version contains the four most significant tables. Additional tables are available online, making the whole report consistent with those from previous years. In the published report, these tables will be referred as 'Supplementary data, Tables SI-SXVIII'. The main results of this report were presented at the annual ESHRE congress in Istanbul, July 2012.
Materials and Methods

Data collection
Data on ART were collected from 34 European countries, covering in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), frozen embryo replacement (FER), egg donation (ED), in vitro maturation (IVM), pooled data on preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) as well as frozen oocyte replacements (FORs). In addition to ART, data on intrauterine inseminations using husband/partner's semen (IUI-H) and donor semen (IUI-D) were also included. The report includes treatments started between 1 January 2009 and 31 December 2009. Data on pregnancy outcomes are derived from follow-up of the cohort treated during this time period.
The method of reporting data in 2009 was similar to that used in the previous year, making almost all tables comparable. A few additional pieces of information were collected regarding the register characteristics (validation process, public access to individual clinical data and financial support) and the number of IVF fresh cycles performed with semen donation or surgically obtained partner's semen. In addition, ED cycles were divided into fresh and frozen replacement categories, and data on embryo donation were also collected. As in 2008, an optional module for data collection on cycles performed for cross-border patients was included. Data were directly entered in ESHRE's computer system by each country co-ordinator, through the software developed by ESHRE. Data analysis was performed in ESHRE's central office by V.G.
As is evident from the tables, the only complete data reported from all countries were on the number of aspirations and the number of clinical pregnancies. The number of transfers was reported from all but a single country (Cyprus), but registers from a number of countries have been unable to provide data on initiated cycles and deliveries; in addition, several countries had a high percentage of pregnancies lost to follow-up. Therefore, complete outcome data were only available on the pregnancy rate per aspiration, while some of the better indicators of treatment success (clinical pregnancies and deliveries per initiated cycle) cannot be reported correctly and caution should be exercised when comparing outcomes among countries.
Total values (in terms of numbers and percentages) presented in the tables refer to those countries where all data have been reported, as underlined in the footnotes.
Definitions refer to The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and World Health Organization glossary of ART terminology (Zegers et al., 2009) .
Results
Participation
The present report includes data from 34 (Table I) Table SI ). Switzerland, Ireland and Latvia were able to report data from all but a single centre each. Participation was very low in Greece (8%) and Kazakhstan (20%), and limited in Lithuania (25%) and Bulgaria (40%). Among the countries with the largest populations, the coverage was 100% in Germany, Italy, UK and France, 72% in Russia (74% in 2008) and 66% in Spain (50% in 2008) .
Reporting methods and size of the clinics
Among the 21 countries where reporting was complete (Supplementary data, Table SII), the register was compulsory for 19 (13 held by a National Health Authority and 6 by a Medical Organization) and voluntary for 2 (held by a Medical Organization). Only seven registers were based on individual forms, i.e. cycle-by-cycle data.
In the 13 countries with partial coverage, all the registers were voluntary (three held by a National Health Authority, nine by a Medical Organization and one by personal initiative); only two used individual forms. Fifteen countries (Austria, Belgium, Finland, France, Germany, Hungary, Italy, Montenegro, Poland, Serbia, Slovenia, Spain, Sweden, Switzerland and UK) 12  12  1230  5088  664  61  25  7068  3437  706   Iceland  1  1  275  188  217  126  0  0  806  12 388  2628   Ireland  7  6  1987  1328  744  6  0  0  0  4065   Italy  200  200  8407  39 504  1019  3102  52 032  4338  861   Kazakhstan  10  2  691  250  295  214  20  4  1474   Latvia  4  3  208  287  199  68  762   Lithuania  4  1  61  54  16  131   Macedonia  4  4  647  1325  66  27  2065  4531  999   Moldova  1  1  255  370  0  0  0  0  0  625  728  166   Montenegro  3  3  51  397  34  482  3334  717   Norway  11  11  3139  3314  2076  15  8544  9300  1833   Poland  31  25  285  7566  3534  272  96  280  35  12 068   Portugal  24  24  1475  3405  804  274  11  107  1  6077  2796  568   Romania  12  8  606  323  110  13  1052   Russia  102  73  19 005  13 755  5456  2190  1088  555 Tables SXII and SXIII) . In these countries, the rates varied from 9 to 33% for fresh cycles (mean of 18.5%) and from 0 to 39% for FER (mean of 21.0%). The figures may be an underestimate because of pregnancies lost to follow-up. In the 13 countries with the complete follow-up, the figures were 21.5% for fresh cycles and 18.3% for FER.
Pregnancies and deliveries after treatment
ED was reported by 22 countries (Supplementary data, Table SVII ). In most of the countries where data were not reported, the technique was illegal. For the first time, the donor cycles (aspirations) and the recipient cycles (transfers) were divided into fresh or frozen/thawed cycles. Frozen/thawed cycles include oocyte or embryo cryopreservation. The mean pregnancy rate was 45.7% in fresh transfers and 31.3% in thawed transfers. In total, 9086 clinical pregnancies resulted from 21 499 embryo transfers with a pregnancy rate of 42.3% per transfer (43.2% in 2008) . The mean delivery rates were 30.2% per transfer and 30.0% per donation in the countries reporting deliveries. The pregnancies lost to follow-up were 1323 (15%).
Eleven countries reported data on embryo donation: 963 transfers were performed, with 397 pregnancies (41.2%) and 210 deliveries (21.8%).
In total, 109 239 infants were recorded as having been born as a consequence of IVF, ICSI, FER and ED in the 30 countries where the reporting included newborns (Table II) . In the countries with 100% coverage with the relevant data, the percentage of babies conceived through ART on the national births varied from 0.6% in Moldova to 4.5% in Denmark. More details are provided in Supplementary data, Table SI, showing that the percentage of ART babies was .3.0% in most of the Nordic countries, and between 1.4 and 2.0% in most of the largest European countries (France, Germany, Italy and UK).
Of the 109 239 ART infants, 86 769 (79.4%) were born after IVF/ICSI fresh cycles, 15 126 (13.9%) after FER and 7344 (6.7%) after ED. In Finland, Iceland and Switzerland, one of three ART infants was born after FER.
Age distribution
The age distribution of women treated with IVF and ICSI varied across countries (Supplementary data, Tables SVIII and SIX). The highest percentages of women aged 40 years or more were found in Greece and Italy, whereas the highest percentages of women aged 34 years or less were found in Czech Republic, Kazakhstan, Lithuania, Poland and Ukraine. As expected, pregnancy rates associated with IVF and ICSI decreased with advancing age. The same trend was seen for delivery rates. FER cycles (Supplementary data, Table SX) included a relatively higher percentage of young women (≤34 years) and, as in fresh cycles, pregnancies and deliveries rates decreased with age. In ED cycles (Supplementary data, Table SXI), the age of the recipient was 40 years or more in 56.2% of cases on average, and few countries reported a figure ,40%: Denmark (31.4%), Hungary (24.6%), Macedonia (16.7%), Slovenia (33.3%) and Sweden (10.6%). Pregnancy and delivery rates in oocyte recipients were comparable across different age groups. Cyprus reported a total of 411 deliveries but no data on multiplicity; these deliveries are not included in the calculation of ART infants. ART, assisted reproductive technology; ED, egg donation; FER, frozen embryo replacement; ICSI, intracytoplasmic sperm injection.
a ART infants also include ED. For IVF and ICSI, there were 599 deliveries with the unknown outcome. These were accepted as singletons to calculate the ART infants. For FER, there were 48 deliveries with the unknown outcome. These were accepted as singletons to calculate the ART infants. For ED, there were 679 deliveries with the unknown outcome. These were accepted as singletons to calculate the ART infants.
b
Total rates refer to these countries where all data were reported for the given technique:
ART in Europe, 2009
Number of embryos transferred and multiple births 
Perinatal risks and complications
Supplementary data, Table SXIV summarizes the risk of preterm deliveries according to the number of newborns. Data were available from 19 countries. These show that the risk of extreme preterm birth (gestational weeks 20 -27) increased from 0.9% for a singleton delivery, to 3.0% for twins and 13.6% for triplets. The same trend was noted for very preterm birth (28-32 weeks), from 1.8 to 9.5% and 38.5%, respectively. Term delivery (37+ weeks) rate was 88.6% for singleton, 48.5% for twins and only 10% for triplets.
Ovarian hyperstimulation syndrome (OHSS) was reported in 27 of the 34 countries (Supplementary data, Table SXV ). In total, 2137 cases of OHSS were recorded, corresponding to a prevalence of 0.8% of all stimulated cycles in the countries reporting the data. The table also includes data on the incidence of other adverse outcomes, such as bleeding (570 cases), infection (61 cases) and fetal reductions (484 cases).
PGD/PGS
PGD/PGS activity, recorded from 15 countries (16 in 2008), involved 4278 cycles, 4048 aspirations, 2994 embryo transfers, 1031 pregnancies (25.5% per aspiration) and 660 deliveries (16.3% per aspiration), the main contributor being Spain with 1706 cycles. More complete data and detailed analysis of PGD/PGS in Europe will be published separately by ESHRE's PGD Consortium (Goossens et al., 2012) .
In vitro maturation
IVM was recorded in nine countries (Table I) 
Frozen oocyte replacement
FOR was recorded by 10 countries, with a total of 4278 thaws, 3416 transfers, 710 pregnancies and 426 deliveries. The majority (72%) was performed in Italy.
Intrauterine insemination
The number of IUI laboratories present in the countries was recorded in 2009 for the first time. Only 19 countries reported the figure, with a total of 1000 units, 872 of which (87%) were reporting to the European IVFmonitoring (EIM) Consortium. Table SXVII for IUI-D). The delivery rate associated with IUI-H declined with age (8.0% below 40 versus 3.3% above) and the multiple delivery rate decreased from 11.0 to 4.5% for twins, and from 1.0 to 0.0% for triplets. Similar findings were seen in IUI-D, where delivery rates decreased from 13.7 to 6.0%, twin deliveries from 10.8 to 1.0% and triplets from 0.5 to 0.0%.
Cumulative delivery rates
Supplementary data, Table SXVIII gives an estimate of the cumulative delivery rates per initiated stimulated cycle in countries performing FER and reporting deliveries. The calculation, presented as the sum of fresh and FER pregnancies obtained during the same year, is not a true cumulative delivery rate per couple per cycle, but it shows that the delivery rate (fresh versus cumulative) can increase in the countries reporting the relevant data. Overall, the increase after inclusion of FER deliveries was from 19.8 to 23.6% (+19%), but in some countries (Switzerland, Finland, Iceland, Sweden and Belgium) the increment resulted more substantial (+59, +58, +48, +37, +32%, respectively). Additionally, the table shows the rate of multiple deliveries after the 'fresh' cycles and the FER combined. The overall multiple delivery rate was particularly low in Sweden and Finland: 5.8 and 8.7%, respectively, with relatively high cumulative delivery rates (32.7 and 35.8%).
Cross-border reproductive care
Only six countries reported data on cross-border patients: Croatia, Iceland, Ireland, Macedonia, Poland and Spain. A total of 6248 cycles were reported, 75.3% of which involved IVF/ICSI with the couple's Sweden own gametes, 15.5% were oocyte donations and 9.2% were IUI or IVF with semen donation. Complete information regarding the countries of origin was reported only from Spain, where 63% of the patients were from Italy, 16% from France, 11% from Germany, 4% from UK and 6% from others. The main reason (68%) reported by patients was to seek access to techniques that were not legally available in their home countries.
Discussion
The present report is the 13th, consecutive annual European report on ART data. Taken together, these reports cover treatment cycles from 1997 to 2009. As shown in the tables, the method of reporting varies among countries and registers from a number of countries have been unable to provide some of the relevant data, such as initiated cycles and deliveries. It can be argued that as long as data are incomplete and generated through different methods of collection, results should be interpreted with caution. Nevertheless, the findings reported in this paper reveal important trends in practice and outcomes in Europe and give a clear picture of the differences existing among countries.
In comparison with 2008, the number of countries reporting to the ESHRE's EIM Consortium decreased to 34: Albania, Bosnia, Estonia and Turkey were not able to contribute data, while Croatia and Cyprus re-joined the Consortium. Most of the independent European states that have never contributed data are very small countries (Andorra, Città del Vaticano, Liechtenstein, Luxemburg, Monaco and San Marino). Data have never been available from Malta and the republic of Belarus, but overall, EIM has been collecting data from .80% of the European countries for several years.
In 2009, the coverage was 85.2% of all clinics, a figure similar to 2008 (84.5%) and 2007 (86%). The number of countries with 100% coverage increased to 21 (19 in 2008) . As in previous years, the lowest reporting rate was from Greece (4 of 50 clinics).
Overall, the number of reported cycles increased by 1.0% since 2008 (+5203), reaching a total of 537 463 despite fewer countries contributing data. Elsewhere in the world in 2009, 146 244 cycles were reported from the USA (CDC, 2011) and 70 541 cycles from Australia and New Zealand (AIHW, 2011) .
As shown in Table I and Supplementary data, Table SI , the average number of treatment cycles per million inhabitants in the countries with 100% coverage was 1067. Huge differences in access exist among countries, with the highest figures from Denmark (2726), Iceland (2628) and Belgium (2574) and the lowest from Moldova (166). A better way to define the availability of ART is to use women of reproductive age (15 -49 years) as the denominator, which eliminates the impact of age differences across the countries (Table I and Supplementary data,  Table SI ). There were also striking differences in access, ranging from 728 cycles in Moldova to 14 160 in Denmark, 13 173 in Belgium and 12 388 in Iceland. Countries able to provide over 8000 cycles per million women of reproductive age and over 1700 cycles per million inhabitants were the Czech Republic, Finland, Norway, Slovenia and Sweden. Overall, the highest availability was reported by Nordic countries. Finally, the percentage of newborns conceived through ART varied from 0.6% in Moldova to 4.6% in Denmark (Supplementary data, Table SI) .
For the first time, the proportion of ICSI versus conventional IVF procedures showed a marginal decrease compared with data from the ART in Europe, 2009 previous year (66% in 2009 and 69% in 2008) , but the figure is likely to have been driven by the absence of data from Turkey, a country with a very high proportion of ICSI cycles (98%) in the previous year. In Australia and New Zealand, 65.6% of all cycles used ICSI in 2009 and in the USA, the corresponding figure was 72.9%, reflecting an uniform trend throughout the world in performing ICSI in the majority of the cycles. The marked increase in the use of ICSI cannot be explained by a similar increase in male infertility but rather by a more liberal use of this technique in cases with mixed infertility, unexplained infertility, mild male factor infertility and fertilization failures (Jain and Gupta, 2007; Nyboe Andersen et al., 2008b) . This is, however, unlikely to fully account for the observed differences, which can only be explained by differences in professional strategy and clinical decision-making. In the USA, 53% of ICSI cycles were performed in couples without a diagnosis of male factor infertility (CDC, 2011) .
Overall, in 2009, the number of transfers with 3+ embryos (18.1%) was significantly lower compared with 2008 (24.4%), while the mean percentage of SETs increased from 22.4 to 24.2% and the proportion of DET from 53.2 to 57.7%. For the first time since 1997, the proportion of 3+ embryos transfers was ,20% and the proportion of SETs was higher than that of triple embryos transfers. The highest proportions of SETs were found in Sweden (70.7%), Norway (53.4%), Belgium (48.9%) and Denmark (42.0%). In contrast, .50% of 3+ embryo transfers were reported in Bulgaria, Greece, Italy, Lithuania, Moldova, Montenegro and Serbia. The EIM reports are unable to discriminate between elective SET (eSET) versus SET in general, but the increase in the number of transfers of one embryo seen in the last years is undoubtedly due to a increase in eSET. Despite huge differences in embryo transfer policy across countries, the overall trend towards transferring fewer embryos seen over the last 10 years seems to continue. Similar observations can be made for the multiple delivery rates. In 2009, the multiple delivery rates (twins + triplets) were marginally lower compared with the previous years: 20.2 versus 21.7% in 2008, 22.3% in 2007 and 20.8% in 2006 . Overall, a remarkable reduction in triplet deliveries over the years is seen (3.6% in 1997 and 0.8% in 2009), but major differences are still evident across countries (Table III) . Some countries registered a triplet delivery rate of .2.5% (Bulgaria, Croatia, Greece, Lithuania, Romania and Serbia), while several other countries were able to maintain the triplets deliveries at ≤0.2% (Belgium, Denmark, Finland, Iceland, Norway, Slovenia, Sweden, Switzerland and The Netherlands). The twin delivery rate ranged from ,10% in Finland and Sweden to .30% in Lithuania, Macedonia and Serbia.
We have included data describing preterm birth rates according to the number of fetuses in the pregnancy (Supplementary data, Table SXIV), which was completed by 19 countries. The risk of extreme preterm birth (,28 weeks) was increased 3-fold for twins and 13-fold for triplets. The risk of very preterm (28 -32 weeks) birth is increased almost 5-fold for twins and 20-fold for triplets.
Fetal reductions are almost always performed in triplet or higherorder gestations. Thus, when analysing the range of triplet delivery rates in different countries, the number of fetal reductions should also be considered. A total of 484 procedures were reported (90 more than in 2008). However, the number is likely to be an underestimate since several countries, including large countries as Germany and Italy, did not report on this intervention. Without fetal reductions, the proportion of triplet deliveries would have been much higher than the number of recorded triplet deliveries (623 in total).
The In comparison with the situation in Europe, data from other registers show that SET was performed in 69.7% of cycles in Australia and New Zealand (AIHW, 2011) and 14% in the USA (CDC, 2011). The delivery rates in Europe remain lower than in the USA, where in fresh non-donor cycles performed in 2008 the delivery rate per aspiration was 33.8% (33.6% in IVF and 33.9% in ICSI) and the delivery rate per transfer was 36.6% (CDC, 2011). However, outcomes were very similar to those achieved in Australia and New Zealand, where the delivery rates in fresh cycles were 23.0% per transfer and 19.7% per aspiration (AIHW, 2011) .
Data on deliveries and infants must be considered and compared with some caution because of the difficulties met by several European countries in gathering pregnancy outcome (Supplementary data, Tables SXII and SXIII), while the pregnancy loss to follow-up was close to 0% in the annual reports both in the USA and in Australia/New Zealand.
Figures for multiple-infant birth rate (twins, triplets or more) point to important differences between the USA (31.6%), Europe (20.2%) and Australia/New Zealand (8.2%).
With the noticeable decline in the number of embryos transferred and the increasing proportion of FER cycles, the cumulative delivery rate per started cycle may be the most relevant end-point for ART. However, this figure can only be obtained a few years after the initial oocyte aspiration. In Supplementary data, Table SXVIII, the cumulative delivery rate is presented as the sum of fresh and FER pregnancies obtained in the same calendar year. The method of calculation can be methodologically flawed, but the estimate may be close to the actual figure. In several countries, FER deliveries added substantially to the delivery rates per cycle: Finland (22.6-35.8%), Belgium (18.4-24.1%), and Norway (23.5-29.2%), justifying their transfer and freezing policies.
Regarding direct risks of ART, OHSS was recorded in 0.8% of all stimulated cycles. However, there may be a degree of under-reporting of this complication as the rate varied between 0 and 2.6% in the countries reporting it.
For the eighth consecutive year, the present report includes European data on treatments with IUI-H (162 843 cycles) and IUI-D (29 235), which show an increase compared with 2008 and 2007. Since the inception of IUI data collection, no differences have been noted in terms of delivery rates and in the incidence of multiple pregnancies.
In 2009, the EIM Consortium decided to continue to address the phenomenon of cross-border reproductive care (CBRC). An optional module was added to the data collection sheets asking for the numbers of CBRC patients, the type of treatment requested, main countries of origin and the reason for travelling abroad. A total of 6248 cycles were reported by six countries. As in 2008, the number was much lower compared with the estimation, based on the CBRC study performed recently in Europe (Shenfield et al., 2010) : 11 000 -14 000 patients and 25 000 -30 000 cycles per year. In addition, only incomplete information was reported regarding the countries of origin and reasons for travelling. Starting to collect the new data is always difficult. However, because the CBRC phenomenon raises important public health concerns and underlines the need for a detailed evaluation, the Consortium will continue to gather data in the coming years.
In summary, the 13th ESHRE report on ART for Europe shows a continuing expansion in the number of treatment cycles, with more than half a million cycles reported in 2009. The use of ICSI has reached a plateau. Pregnancy and delivery rates after IVF and ICSI remained relatively stable, compared with 2008 and 2007. The number of multiple embryo transfers (3+ embryos) and the multiple delivery rate have shown a clear decline.
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